MCID: TNG007
MIFTS: 54

Tongue Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Rare diseases, Smell/Taste diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Tongue Carcinoma

Summaries for Tongue Carcinoma

Disease Ontology: 11 A tongue cancer that derives from epithelial cells that cover the surface of the tongue.

MalaCards based summary: Tongue Carcinoma, also known as tongue cancer, is related to tongue squamous cell carcinoma and lip and oral cavity cancer, and has symptoms including glossalgia An important gene associated with Tongue Carcinoma is BCYRN1 (Brain Cytoplasmic RNA 1), and among its related pathways/superpathways are Signal Transduction and GPCR Pathway. The drugs Sargramostim and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include tongue, tonsil and lymph node, and related phenotypes are homeostasis/metabolism and neoplasm

Related Diseases for Tongue Carcinoma

Diseases related to Tongue Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 362)
# Related Disease Score Top Affiliating Genes
1 tongue squamous cell carcinoma 31.3 TP53 MMP9 MIR21 MAU2 MALAT1 DNAJB7
2 lip and oral cavity cancer 30.9 TP53 RB1 MMP9 MMP2 MIR21 CDH1
3 head and neck cancer 30.9 VEGFA TP53 MMP9 MIR21 DNAJB7 CDH1
4 squamous cell carcinoma 30.8 VEGFC VEGFA TP53 RB1 MMP9 MMP2
5 keratoacanthoma 30.6 TP53 CDKN1A CDH1 BCL2L1
6 polyploidy 30.4 TP53 CDKN1A
7 periodontitis, chronic 30.3 MMP8 MMP1
8 oropharynx cancer 30.3 VEGFA TP53 MIR21 CDH1
9 papilloma 30.3 VEGFA TP53 RB1 CDKN1A CDH1
10 pulmonary emphysema 30.2 VEGFA MMP9 MMP8 MMP2 MMP1
11 larynx cancer 30.2 TP53 MMP2 MIR21 FAM3D-AS1
12 lymphoma, hodgkin, classic 30.2 TP53 MIR21 MDM2 BCL2L1
13 meningioma, familial 30.2 VEGFA TP53 MMP9 MDM2 CDH1
14 endometriosis 30.2 VEGFA TP53 MMP2 MMP1
15 rhabdomyosarcoma 2 30.2 TP53 RB1 MDM2
16 periodontitis 30.1 MMP9 MMP8 MMP2 MMP13 MMP1 MIR21
17 b-cell lymphoma 30.1 TP53 RB1 MDM2 MALAT1 CDKN1A BCL2L1
18 nasopharyngeal carcinoma 30.1 VEGFC VEGFA TP53 MMP9 MMP2 MIR21
19 rhabdomyosarcoma 30.1 VEGFA TP53 RB1 MMP2 MDM2 CDKN1A
20 esophageal cancer 30.1 VEGFC VEGFA TP53 RB1 MMP9 MMP2
21 squamous cell carcinoma, head and neck 30.0 VEGFC VEGFA TP53 RB1 MMP9 MMP2
22 lung cancer susceptibility 3 30.0 VEGFC VEGFA TP53 RB1 MMP9 MMP2
23 pancreatic cancer 29.7 VEGFC VEGFA TP53 RB1 MMP9 MMP2
24 bladder cancer 29.7 VEGFC VEGFA TP53 RB1 MMP9 MMP2
25 leukemia, chronic lymphocytic 29.7 VEGFA TP53 MIR21 MDM2 BCL2L1
26 melanoma 29.7 VEGFC VEGFA TP53 RB1 MMP9 MMP2
27 gastric cancer 29.6 VEGFC VEGFA TP53 RB1 MMP9 MMP2
28 hepatocellular carcinoma 29.6 VEGFC VEGFA TP53 RB1 MMP9 MMP2
29 lung cancer 29.5 VEGFC VEGFA TP53 RB1 MMP9 MMP2
30 esophagus verrucous carcinoma 10.5 TP53 MDM2 CDH1
31 amaurosis fugax 10.5 MMP9 MMP8
32 suppressor of tumorigenicity 3 10.5 TP53 RB1 CDKN1A
33 spastic entropion 10.5 MMP9 MMP2 MMP1
34 dentin caries 10.5 MMP9 MMP8 MMP2
35 tendinopathy 10.5 MMP8 MMP1
36 metaphyseal anadysplasia 10.5 MMP9 MMP13
37 apocrine adenosis of breast 10.5 TP53 BCL2L1
38 familial retinoblastoma 10.5 TP53 RB1 MDM2
39 gastroesophageal junction adenocarcinoma 10.5 VEGFC VEGFA TP53
40 conjunctivochalasis 10.5 MMP9 MMP2 MMP1
41 pancreatic ductal carcinoma 10.5 VEGFA TP53 CDH1
42 corneal ulcer 10.5 VEGFA MMP9 MMP2
43 spinal stenosis 10.5 MMP2 MMP13 MMP1
44 anaplastic oligodendroglioma 10.4 VEGFA TP53 MDM2
45 maxillary sinus adenocarcinoma 10.4 TP53 MDM2
46 gum cancer 10.4 MAU2 DNAJB7
47 parotid gland cancer 10.4 TP53 BCYRN1
48 gingival disease 10.4 MMP9 MMP8 MMP1
49 esophagus adenocarcinoma 10.4 TP53 MIR21 CDH1
50 pelvic inflammatory disease 10.4 MMP9 MMP2 CDH1

Comorbidity relations with Tongue Carcinoma via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition Swallowing Disorders

Graphical network of the top 20 diseases related to Tongue Carcinoma:



Diseases related to Tongue Carcinoma

Symptoms & Phenotypes for Tongue Carcinoma

UMLS symptoms related to Tongue Carcinoma:


glossalgia

MGI Mouse Phenotypes related to Tongue Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.24 BCL2L1 CDH1 CDKN1A DNAJB7 MALAT1 MDM2
2 neoplasm MP:0002006 10.2 BCL2L1 CDH1 CDKN1A MDM2 MMP1 MMP2
3 no phenotypic analysis MP:0003012 9.98 CDH1 CDKN1A MALAT1 MDM2 RB1 TP53
4 limbs/digits/tail MP:0005371 9.95 CDKN1A MDM2 MMP13 MMP9 RB1 TP53
5 digestive/alimentary MP:0005381 9.92 CDH1 CDKN1A MDM2 MMP2 MMP9 RB1
6 cardiovascular system MP:0005385 9.9 CDH1 CDKN1A MDM2 MMP13 MMP2 MMP8
7 craniofacial MP:0005382 9.8 CDKN1A MAU2 MDM2 MMP2 RB1 TP53
8 immune system MP:0005387 9.77 BCL2L1 CDH1 CDKN1A MALAT1 MDM2 MMP1
9 integument MP:0010771 9.36 BCL2L1 CDH1 CDKN1A DNAJB7 MDM2 MMP13

Drugs & Therapeutics for Tongue Carcinoma

Drugs for Tongue Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sargramostim Approved, Investigational Phase 3 123774-72-1
2
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
3
Bevacizumab Approved, Investigational Phase 3 216974-75-3 135329020
4
Fluorouracil Approved Phase 3 51-21-8 3385
5
Molgramostim Investigational Phase 3 99283-10-0
6 Antimitotic Agents Phase 3
7 Tubulin Modulators Phase 3
8 Immunoglobulin G Phase 3
9 Antimetabolites Phase 3
10 Endothelial Growth Factors Phase 3
11 Mitogens Phase 3
12
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030
13
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
14
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
15
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
16
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
17
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
18
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
19
Acetylcysteine Approved, Investigational Phase 2 616-91-1 581 12035
20
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908
21
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
22
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
23 Raspberry Approved Phase 1, Phase 2
24
Erlotinib Approved, Investigational Phase 2 183319-69-9, 183321-74-6 176870
25
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
26
Trioxsalen Approved Phase 2 3902-71-4 5585
27
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
28
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
29
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
30
Aspartic acid Approved, Nutraceutical Phase 1, Phase 2 56-84-8 5960
31
Arginine Approved, Investigational, Nutraceutical Phase 1, Phase 2 74-79-3 6322
32
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
33
Cediranib Investigational Phase 2 288383-20-0 9933475
34
Maleic acid Experimental, Investigational Phase 2 110-16-7, 110-17-8 444266 444972
35
Saracatinib Investigational Phase 2 379231-04-6 10302451
36
Dihematoporphyrin ether Investigational Phase 2 97067-70-4
37
Diethyl ether Experimental Phase 2 60-29-7 3283
38
MK-1775 Investigational Phase 2 955365-80-7 24856436
39 Anesthetics Phase 2
40 Soy Bean Phase 2
41 Immunosuppressive Agents Phase 2
42 Immunologic Factors Phase 2
43 Anti-Bacterial Agents Phase 2
44 Anti-Infective Agents Phase 1, Phase 2
45 Antifungal Agents Phase 2
46 Antibiotics, Antitubercular Phase 2
47 Histone Deacetylase Inhibitors Phase 2
48 Albumin-Bound Paclitaxel Phase 2
49 Antiviral Agents Phase 2
50 Expectorants Phase 2

Interventional clinical trials:

(show top 50) (show all 75)
# Name Status NCT ID Phase Drugs
1 Management of Mucositis With GM-CSF (Sargramostim) Mouthwash Study Protocol Completed NCT00293462 Phase 3
2 A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
3 Role of Neo-adjuvant Chemotherapy in Organ Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue Unknown status NCT02985255 Phase 2 Docetaxel;Cisplatin;5FU
4 Phase II Clinical Trial of AZD2171 Monotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Patients Completed NCT00458978 Phase 2 Cediranib Maleate
5 A Phase II Trial of Preoperative Soy Isoflavone Supplementation and Molecular Markers in the Prevention of Head and Neck Squamous Carcinoma Completed NCT02007200 Phase 2 Soy Isoflavones
6 A T1 Translational Multicenter Randomized Phase II Study of Temsirolimus Versus Cetuximab Plus Temsirolimus in Patients With Recurrent / Metastatic Head and Neck Cancer, Who Failed Prior EGFR Based Therapy Completed NCT01256385 Phase 2 Temsirolimus
7 A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Subjects With Locally Advanced, Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC) Completed NCT01175980 Phase 2 Vorinostat
8 A Phase 2 Study of Dasatinib in Head and Neck Squamous Cell Carcinoma Completed NCT00507767 Phase 2 dasatinib
9 A Phase II Study of AZD0530 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Completed NCT00513435 Phase 2 saracatinib
10 A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies Completed NCT02123511 Phase 2 acetylcysteine
11 High-activity Natural Killer Immunotherapy for Small Metastases of Tongue Cancer Completed NCT03008330 Phase 1, Phase 2
12 A Phase 2 Trial of GW572016 in Patients With Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck Completed NCT00114283 Phase 2 lapatinib ditosylate
13 Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (Velcade TM) in Combination With Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
14 Phase II Evaluation of BAY 43-9006 (NSC-724772) in Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
15 A Randomized Phase II Study of BMS-247550 (NSC #710428) Given Daily x 5 Days Every 3 Weeks or Weekly in Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
16 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab in Patients With Refractory, Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00939627 Phase 2 sorafenib tosylate
17 Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial Completed NCT00330382 Phase 2 Bowman-Birk inhibitor concentrate
18 Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135] Completed NCT00064103 Phase 1, Phase 2
19 A Biomarker Driven Pilot Study of the Pan-class I PI3K Inhibitor NVP-BKM120 in Combination With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer Completed NCT01816984 Phase 1, Phase 2 PI3K inhibitor BKM120
20 Phase II Trial of Carboplatin/Paclitaxel and Cetuximab, Followed by Carboplatin/Paclitaxel/Cetuximab and Erlotinib, With Correlative Studies in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
21 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
22 Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer Completed NCT01469429 Phase 1, Phase 2 chemoprevention
23 Combination of Cryosurgey and NK Immunotherapy for Recurrent Tongue Cancer Completed NCT02849379 Phase 1, Phase 2
24 Concurrent Chemoradiation Versus Induction Docetaxel, Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy in Locally Advanced Hypopharyngeal and Base of Tongue Cancer: A Randomized Phase II Study Completed NCT01312350 Phase 2 neoadjuvant docetaxel/cisplatin/fluorouracil;No treatment before definitive CCRT
25 A Pilot Trial Targeting mTOR as a Novel Mechanism-Based Neoadjuvant Therapy for Head and Neck Cancer Completed NCT01195922 Phase 1, Phase 2 Sirolimus
26 Phase II Study: Induction Chemotherapy Followed by Transoral Robotic Surgery and Neck Dissection for Definitive Management of Oropharyngeal Squamous Cell Carcinoma. (NECTORS Trial) Recruiting NCT04277858 Phase 2 Docetaxel
27 Defining a Personalized Hypoxic Radiation Target Through Correlation of Functional F18-FAZA PET Imaging to Pimonidazole-stained 3D Whole-mounted Histological Specimen Recruiting NCT03181035 Phase 1, Phase 2 Pimonidazole
28 A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer Active, not recruiting NCT02254278 Phase 2 Cisplatin
29 A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies Active, not recruiting NCT03602079 Phase 1, Phase 2 A166
30 Effect of COX-2 (Cyclooxygenase-2) and EGFR (Epidermal Growth Factor Receptor) Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study. Active, not recruiting NCT02748707 Phase 2 Arm1;Arm 2;Arm 3
31 Interstitial Photodynamic Therapy During Standard Chemotherapy for Palliation of Patients With Head and Neck Squamous Cell Carcinoma - Phase II Terminated NCT02068157 Phase 2 Photodynamic Therapy;Porfimer Sodium
32 A Randomized Phase II Trial of Cisplatin With or Without Wee1 Kinase Inhibitor AZD1775 (MK-1775) for First-line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (RM-SCCHN) Terminated NCT02196168 Phase 2 Cisplatin;WEE1 Inhibitor AZD1775
33 A Phase II Study of Tongue Conservation Surgery for Advanced Oral Tongue Cancer: Induction Chemotherapy, Followed by Tongue Conservation Surgery and Postoperative Chemoradoitherapy Terminated NCT03161548 Phase 2 Induction chemotherapy
34 Randomized Phase II Trial of Transoral Endoscopic Head And Neck Surgery Followed by Risk-Based IMRT and Weekly Cisplatin Versus IMRT and Weekly Cisplatin for HPV Negative Oropharynx Cancer Withdrawn NCT01953952 Phase 2 cisplatin
35 A Phase 2 Placebo Controlled Randomized Study of the Effect of SAMITAL on Severity and Duration of Mucositis Induced by Chemoradiation for Head and Neck Cancer (HNC) Withdrawn NCT01674374 Phase 2 Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules
36 Enhancement of Cetuximab-Induced Antibody-Dependent Cellular Cytotoxicity (ADCC) With Lenalidomide in Advanced Solid Tumors: A Phase I/IB Study Completed NCT01254617 Phase 1 Lenalidomide
37 A Phase I/II Clinical Trial of Sorafenib in Combination With Cisplatin and Docetaxel in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT02035527 Phase 1 sorafenib tosylate;cisplatin;docetaxel
38 A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
39 Implementation of an Intraoral Stent in Radiotherapy of Tongue Cancer Completed NCT04337853 Phase 1
40 A Phase I Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, OSI-774, in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck Completed NCT00049283 Phase 1 erlotinib hydrochloride;docetaxel
41 A Phase I Evaluation of Cetuximab and RAD001 in Patients With Solid Tumors Completed NCT01637194 Phase 1 everolimus
42 Phase I Clinical Trial of VTX-2337, a Small Molecule Toll-Like Receptor 8 (TLR8) Agonist in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN) Completed NCT01334177 Phase 1 TLR8 agonist VTX-2337
43 Proton Image-Guided Radiation Assignment for Therapeutic Escalation Via Selection of Locally Advanced Head and Neck Cancer Patients [PIRATES] Recruiting NCT04870840 Phase 1
44 Nab-Paclitaxel-based Re-induction Chemotherapy Followed by Response-stratified Chemoradiotherapy in Patients With Previously Treated Squamous Cell Carcinoma of the Head and Neck. Active, not recruiting NCT01847326 Phase 1 carboplatin;paclitaxel albumin-stabilized nanoparticle formulation;fluorouracil;hydroxyurea
45 A Phase 1, Open Label, Multi-Center, Single and Multiple Dose, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S in Previously Treated Patients With Advanced or Metastatic Cancers With High LAT1 Signatures, and in Patients With Relapsed or Refractory Grade 4 Astrocytoma Active, not recruiting NCT04430842 Phase 1 QBS10072S
46 A Phase I Trial of Concurrent Chemoradiation/Chemoreirradiation With Cetuximab (ERBITUX®), Sunitinib, and Accelerated Radiation in Patients With Locally Advanced/High-risk/Recurrent Poor Prognosis Head and Neck Cancer Terminated NCT00906360 Phase 1 sunitinib malate
47 A Phase Ib Immunomodulatory Study of Single Agent Talactoferrin in Patients With Select Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC) and Squamous Head and Neck Cancer (HNSCC) Terminated NCT01528137 Phase 1
48 A Phase I Study of CBLB502 in the Treatment of Patients With Poor Prognosis Advanced Squamous Cell Carcinomas of the Head and Neck Receiving Chemoradiotherapy Withdrawn NCT01728480 Phase 1 entolimod;cisplatin
49 A Phase I Dose Escalation Study of the mTOR Inhibitor Everolimus (RAD001) and Erlotinib Concurrently With Radiation Therapy in the Re-Irradiation Setting for Head and Neck Cancer Withdrawn NCT01332279 Phase 1 everolimus;erlotinib hydrochloride
50 Use of Transoral Ultrasound for Measuring Depth Of Invasion in Oral Tongue Carcinoma, and Comparing Obtained Measurements With Measurements From MRI With the Results Obtained From Pathological Examination of Surgically Resected Specimens Unknown status NCT04614896

Search NIH Clinical Center for Tongue Carcinoma

Cochrane evidence based reviews: tongue neoplasms

Genetic Tests for Tongue Carcinoma

Anatomical Context for Tongue Carcinoma

Organs/tissues related to Tongue Carcinoma:

MalaCards : Tongue, Tonsil, Lymph Node, Lung, Endothelial, Myeloid, Bone

Publications for Tongue Carcinoma

Articles related to Tongue Carcinoma:

(show top 50) (show all 2435)
# Title Authors PMID Year
1
Emodin induces apoptosis of human tongue squamous cancer SCC-4 cells through reactive oxygen species and mitochondria-dependent pathways. 53 62
19331169 2009
2
Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer. 53 62
18253113 2008
3
Prognostic significance of p21WAF1/CIP1, p16INK4a and CD44s in tongue cancer. 53 62
17611661 2007
4
NF-kappaB signaling pathway is involved in growth inhibition, G2/M arrest and apoptosis induced by Trichostatin A in human tongue carcinoma cells. 53 62
17005413 2006
5
Carcinoma of tongue and the buccal mucosa represent different biological subentities of the oral carcinoma. 53 62
16767431 2006
6
Human tongue carcinoma growth is inhibited by selective antigelatinolytic peptides. 53 62
16331606 2006
7
[Effects of arsenic trioxideon the cell apoptosis and hTERT mRNA of human tongue cancer cells]. 53 62
16285558 2005
8
The expression of vascular endothelial growth factor-A and -C, and receptors 1 and 3: correlation with lymph node metastasis and prognosis in tongue squamous cell carcinoma. 53 62
15289890 2004
9
Identification of tumor-associated proteins in oral tongue squamous cell carcinoma by proteomics. 53 62
14730689 2004
10
Molecular analysis of p21 promoter activity isolated from squamous carcinoma cell lines of the head and neck under the influence of 1,25(OH)2 vitamin D3 and its analogs. 53 62
14977084 2004
11
MMP-9 activation by tumor trypsin-2 enhances in vivo invasion of human tongue carcinoma cells. 53 62
12454097 2002
12
Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. 53 62
11900224 2002
13
A comparative study of the clinicopathological significance of E-cadherin and catenins (alpha, beta, gamma) expression in the surgical management of oral tongue carcinoma. 53 62
11206273 2001
14
Inostamycin, an inhibitor of cytidine 5'-diphosphate 1,2-diacyl-sn-glycerol (CDP-DG): inositol transferase, suppresses invasion ability by reducing productions of matrix metalloproteinase-2 and -9 and cell motility in HSC-4 tongue carcinoma cell line. 53 62
11315101 2000
15
p53, p21, Rb, and MDM2 proteins in tongue carcinoma from patients < 35 versus > 75 years. 53 62
10645402 1999
16
Tenascin: growth and adhesion modulation--extracellular matrix degrading function: an in vitro study. 53 62
8736172 1996
17
Expression of the cell-cell adhesion molecule E-cadherin in tongue carcinoma cell lines. 53 62
7829949 1994
18
Circulating prolactin and tumoral prolactin receptors in men with tongue cancer: a preliminary study. 53 62
8181582 1994
19
Genome-wide profiling of dysregulated piRNAs and their target genes implicated in oncogenicity of tongue squamous cell carcinoma. 62
36179965 2023
20
Squamous cell carcinoma of the tongue: subtypes and morphological features affecting prognosis. 62
36252129 2022
21
Corrigendum to "Small interfering RNA targeting ILK inhibits metastasis in human tongue cancer cells through repression of epithelial-to-mesenchymal transition" [Exp. Cell Res., 319 (2013): 2058-2072]. 62
36279619 2022
22
Comparison of quality of life and psychological distress in patients with tongue cancer undergoing a total/subtotal glossectomy or extended hemiglossectomy and free flap transfer: a prospective evaluation. 62
36470693 2022
23
Swallowing: A delayed milestone post-surgery in tongue cancers. 62
36356388 2022
24
Trends in the Prevalence of Cancer in Cardiovascular Diseases: A Single Center Retrospective Study, 2011-2018. 62
36464275 2022
25
Prediction of Occult Lymph Node Metastasis in Early Tongue Cancer. 62
36455879 2022
26
Initial Experience of Intra-Arterial Chemotherapy Using a Novel External Carotid Arterial Sheath System Combined with Radiotherapy and Systemic Chemotherapy for Locally Advanced Tongue Cancer. 62
36428625 2022
27
Surgical Extent for Oral Cancer: Emphasis on a Cut-Off Value for the Resection Margin Status: A Narrative Literature Review. 62
36428794 2022
28
The Expression of Defensin-Associated Genes May Be Correlated With Lymph Node Metastasis of Early-Stage Tongue Cancer. 62
36097842 2022
29
High-Frequency Intraoral Ultrasound for Preoperative Assessment of Depth of Invasion for Early Tongue Squamous Cell Carcinoma: Radiological-Pathological Correlations. 62
36429617 2022
30
The role of magnetic resonance imaging in assessing the extent of tongue squamous cell carcinoma: A prospective cohort study. 62
35257931 2022
31
Eating and speech problems in oral and pharyngeal cancer survivors - Associations with treatment-related side-effects and time since diagnosis. 62
36257925 2022
32
Tertiary lymphoid structures associate with improved survival in early oral tongue cancer. 62
36309667 2022
33
Modified submandibular mandibulotomy approach without lip-splitting in tongue cancer. 62
36104264 2022
34
Ultrasound accurately assesses depth of invasion in T1-T2 oral tongue cancer. 62
36258857 2022
35
The combination of volumetric arc radiation therapy and boost high-dose rate interstitial brachytherapy for T3N2c tongue cancer: a technical report. 62
36239100 2022
36
Prediction of cervical lymph node metastasis from immunostained specimens of tongue cancer using a multilayer perceptron neural network. 62
36307918 2022
37
Practising transoral robotic surgery in a middle-income country: surgical outcomes and early challenges. 62
36183030 2022
38
[Application of anterolateral thigh flap preforming tongue in patients with total glossectomy]. 62
36319129 2022
39
Effect of Ablative Dose Irradiation on Redistribution and Radioresponse in a Mouse Xenograft Model. 62
36223173 2022
40
Head and neck surgery during COVID-19. 62
33552941 2022
41
Contralateral Nodal Metastasis from Tongue Malignancy. 62
36452539 2022
42
Application and accuracy of ultrasound-guided resections of tongue cancer. 62
35901543 2022
43
Oral Cancer Cells Release Vesicles that Cause Pain. 62
35802912 2022
44
A Multicenter Study on the Effect of Margin Distance on Survival and Local Control in Stage 1-2 Squamous Cell Carcinoma of the Tongue. 62
36125567 2022
45
Reply to the Letter concerning "Combination of fluorescence visualization and iodine solution-guided surgery for local control of early tongue cancer". 62
36117008 2022
46
Correction to: Alterations of posterior pharyngeal wall movement during swallowing in postoperative tongue cancer patients: assessment with a videofluoroscopic swallowing study. 62
36085387 2022
47
Prediction of nodal metastasis based on intraoral sonographic findings of the primary lesion in early-stage tongue cancer. 62
36123273 2022
48
Association of high cellular expression and plasma concentration of angiopoietin-like 4 with tongue cancer lung metastasis and poor prognosis. 62
35949602 2022
49
Adequacy of Disease Control by Supraomohyoid Neck Dissection in cT1/T2 Tongue Cancer. 62
36143322 2022
50
Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1). 62
35834946 2022

Variations for Tongue Carcinoma

Expression for Tongue Carcinoma

Search GEO for disease gene expression data for Tongue Carcinoma.

Pathways for Tongue Carcinoma

Pathways related to Tongue Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Super pathways Score Top Affiliating Genes
1 13.79 VEGFC VEGFA TP53 MMP9 MMP2 MDM2
2
Show member pathways
13.55 VEGFC VEGFA TP53 RB1 MMP9 MMP8
3
Show member pathways
13.32 VEGFA TP53 MMP9 MMP2 MMP1 CDKN1A
4
Show member pathways
12.96 VEGFC VEGFA TP53 MDM2 CDKN1A BCL2L1
5
Show member pathways
12.82 MMP9 MMP8 MMP2 MMP13 MMP1
6
Show member pathways
12.74 MMP9 MMP8 MMP2 MMP13 MMP1 CDH1
7
Show member pathways
12.66 VEGFA TP53 RB1 MDM2 CDKN1A CDH1
8 12.5 TP53 RB1 MDM2 CDKN1A
9 12.47 VEGFC VEGFA TP53 MMP9 MMP2 MDM2
10
Show member pathways
12.46 TP53 RB1 MDM2 CDKN1A
11
Show member pathways
12.26 TP53 MDM2 CDKN1A BCL2L1
12
Show member pathways
12.25 TP53 RB1 MDM2 CDKN1A
13
Show member pathways
12.23 TP53 RB1 MDM2 CDKN1A BCL2L1
14
Show member pathways
12.2 BCL2L1 CDKN1A MDM2 RB1 TP53
15 12.19 TP53 MMP9 MMP2 CDH1
16
Show member pathways
12.13 TP53 RB1 MDM2 CDKN1A
17 12.05 MMP9 MMP2 MMP13 CDH1
18 12.04 TP53 RB1 MMP2 MDM2 CDKN1A
19 12.02 VEGFA TP53 RB1 MMP1 MDM2 CDH1
20 12 VEGFA CDKN1A CDH1 BCL2L1
21 11.96 TP53 RB1 MDM2 CDKN1A
22 11.92 TP53 MDM2 CDKN1A
23 11.92 TP53 RB1 CDKN1A BCL2L1
24 11.92 VEGFC VEGFA MMP2 CDH1
25
Show member pathways
11.88 MMP1 MMP13 MMP2 MMP8 MMP9
26 11.87 VEGFC MMP9 MMP2 MMP13
27 11.84 TP53 RB1 MDM2 CDKN1A
28
Show member pathways
11.82 TP53 MDM2 CDKN1A
29
Show member pathways
11.8 MDM2 CDKN1A BCL2L1
30 11.79 TP53 MMP1 MDM2 CDKN1A
31 11.78 VEGFA TP53 MMP9 MMP2 MMP1 CDKN1A
32 11.77 CDKN1A MDM2 RB1
33 11.76 VEGFA TP53 RB1 CDKN1A
34 11.75 MMP9 MMP2 CDH1
35 11.73 TP53 MMP9 MMP1
36 11.73 VEGFA TP53 MMP9 MMP2 MMP1
37 11.73 VEGFA TP53 MMP9 MMP2 MMP1 CDKN1A
38 11.71 TP53 MIR21 CDKN1A
39
Show member pathways
11.7 MMP9 MMP8 MMP2
40
Show member pathways
11.68 VEGFA MMP9 MMP2 MMP1
41 11.65 MMP9 MMP2 MMP13 MMP1
42 11.64 VEGFA MMP9 CDKN1A
43 11.64 VEGFA TP53 RB1 MMP2 MDM2 CDKN1A
44 11.63 RB1 MMP2 BCL2L1
45 11.62 CDKN1A MDM2 RB1
46 11.59 VEGFA MMP9 MMP2
47 11.59 VEGFC VEGFA TP53 MDM2
48 11.5 TP53 MDM2 CDKN1A
49 11.46 BCL2L1 CDKN1A MMP1 TP53 VEGFA
50 11.41 VEGFA TP53 BCL2L1

GO Terms for Tongue Carcinoma

Cellular components related to Tongue Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix GO:0031012 9.28 VEGFA MMP9 MMP8 MMP2 MMP13 MMP1

Biological processes related to Tongue Carcinoma according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.32 VEGFA TP53 MMP9 MIR21 MDM2 BCL2L1
2 positive regulation of protein phosphorylation GO:0001934 10.16 VEGFC VEGFA MMP9 MIR21 CDKN1A
3 extracellular matrix organization GO:0030198 10.16 MMP9 MMP8 MMP2 MMP13 MMP1
4 cellular response to hypoxia GO:0071456 10.11 MALAT1 MDM2 TP53 VEGFA
5 negative regulation of gene expression GO:0010629 10.1 VEGFA TP53 RB1 MMP8 MIR21 CDKN1A
6 ovarian follicle development GO:0001541 10.07 VEGFA MMP2 BCL2L1
7 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 10 MMP9 MMP2 MIR21
8 endodermal cell differentiation GO:0035987 10 MMP9 MMP8 MMP2
9 embryo implantation GO:0007566 9.98 MMP9 MMP2 MIR21
10 positive regulation of mast cell chemotaxis GO:0060754 9.91 VEGFC VEGFA
11 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.91 TP53 MDM2 CDKN1A
12 protein metabolic process GO:0019538 9.89 MMP1 MMP13 MMP2
13 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.88 VEGFA TP53
14 cellular response to actinomycin D GO:0072717 9.85 TP53 MDM2
15 glial cell proliferation GO:0014009 9.85 VEGFC TP53 RB1
16 extracellular matrix disassembly GO:0022617 9.85 MMP9 MMP8 MMP2 MMP13 MMP1
17 maintenance of mitotic sister chromatid cohesion GO:0034088 9.84 RB1 MAU2
18 response to amyloid-beta GO:1904645 9.8 MMP13 MMP2 MMP9
19 negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator GO:1902254 9.79 MIR21 MDM2
20 signal transduction by p53 class mediator GO:0072331 9.73 TP53 CDKN1A
21 cellular response to UV-A GO:0071492 9.73 MMP9 MMP2 MMP1
22 negative regulation of mitotic cell cycle GO:0045930 9.65 MIR21 RB1 TP53
23 collagen catabolic process GO:0030574 9.65 MMP9 MMP8 MMP2 MMP13 MMP1
24 cellular response to gamma radiation GO:0071480 9.28 TP53 MIR21 MDM2 CDKN1A BCL2L1

Molecular functions related to Tongue Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 9.96 MMP9 MMP8 MMP2 MMP13 MMP1
2 metalloendopeptidase activity GO:0004222 9.85 MMP1 MMP13 MMP2 MMP8 MMP9
3 disordered domain specific binding GO:0097718 9.8 TP53 RB1 MDM2
4 vascular endothelial growth factor receptor binding GO:0005172 9.67 VEGFC VEGFA
5 metallopeptidase activity GO:0008237 9.5 MMP9 MMP8 MMP2 MMP13 MMP1
6 endopeptidase activity GO:0004175 9.32 MMP9 MMP8 MMP2 MMP13 MMP1

Sources for Tongue Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....